— Jeff Ward, Lehigh Valley News Briefs
An Australian company is expanding to Bethlehem after raising $2 million in funding, the company said in a statement.
Diag-Nose says it was founded in 2020. Its goal is to use Artificial Intelligence and proteomics (the study of proteins) to provide respiratory care. Diag-Nose is based in Australia.
Its offerings include the ABEL Microsampler, which collects nasal-fluid samples for analysis.
The company said it has raised $2 million in a “seed round.” The so-called seed money is typically used for research and early-stage product development. Diag-Nose will be working on how to treat illnesses including asthma, chronic obstructive pulmonary disorder (COPD) and chronic sinusitis.
“Our goal is to equip physicians with tools to personalize care, improve outcomes, and reduce costs for patients globally,” co-founder and Chief Medical Officer Dr. David Yen said in the company statement.
Among those providing funding, according to Diag-Nose, are Breakthrough Victoria, an Australian investment firm; Radar Ventures; a syndicate of physicians from Specialty Physician Associates (SPA); biotech investors Carl Stubbings, Stephen Ho, and Richard Lipscombe, and physicians.
Lehigh Valley News Briefs 